Drugdocs | Nubeqa

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Nubeqa

Chemical Name	darolutamide
Dosage Form	Tablet (oral; 300 mg)
Drug Class	Receptor antagonists
System	Male reproductive
Company	Bayer HealthCare Pharmaceuticals Inc.
Approval Year	2019

Indication

Nubeqa is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Last updated on 2/1/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Nubeqa (darolutamide) Prescribing Information	2019	Bayer Healthcare

Document Title	Year	Source
Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer.	2020	NICE

Document Title	Year	Source
Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.	2020	American Journal of Clinical Oncology
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.	2020	Clinical Genitourinary Cancer
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials.	2020	Clinical and Translational Oncology
Apalutamide, enzalutamide, and darolutamide for non‑metastatic castration‑resistant prostate cancer: a systematic review and network meta‑analysis.	2020	International Journal of Clinical Oncology
New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes.	2019	Clinical Genitourinary Cancer

Document Title	Year	Source
Advanced prostate cancer: AUA/ASTRO/SUO guideline.	2020	American Urological Association Education and Research